Suzanne Morris, DVM

Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.

To assist clinicians in identifying, monitoring, and managing immune-related adverse effects, the American Society of Clinical Oncology issued guidelines in June 2022 updated by a multidisciplinary panel.

According to Andrew S. Barbas, MD, of Duke Health, the scarcity of testing that can provide accurate results in patients with pancreatic cancer contributes to diagnoses in the advanced stages of the disease and consequently to poor prognoses.

In chronic lymphocytic leukemia management, many patients do not fall within the category to receive chemoimmunotherapy. However, for high-risk patients, targeted agents are changing the treatment landscape.

Several novel therapeutics have gained approval from the European Medicines Agency for the treatment of patients with bladder cancer in recent years, prompting the European Society for Medical Oncology to issue an eUpdate to these guidelines in August of 2019.